ZIM faces significant headwinds from industry overcapacity, likely leading to years of low rates and ongoing cash burn despite its strong current cash position. Dividend prospects are bleak after Q3, ...
HOUSTON, TX / ACCESS Newswire / February 26, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results